Although several new molecules such as IDH1 mutation, MGMT promoter methylation, and 1p/19q chromosome codeletion have been applied for diagnosis and treatment in gliomas, the prognosis of patients remains unsatisfactory, which drives us to explore more effective and credible factors. The gene discussed is IDH1; the disease is glioma.